Appendix B

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (review of Technology Appraisal 205)

Final matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • GlaxoSmithKline (eltrombopag) Patient/carer groups • Afiya Trust • Black Health Agency • Equalities National Council • Independent Age • ITP Support Association • Muslim Council of Great Britain • Muslim Health Network • South Asian Health Foundation • Specialised Healthcare Alliance • Splenectomy Trust UK Professional groups • Association of Surgeons of Great Britain and Ireland • British Association for Services to the Elderly • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatric Society • British Society for Haematology • National Blood Service • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum	General • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • National Public Health Service for Wales • NHS Alliance • NHS Confederation • Scottish Medicines Consortium Comparator manufacturer(s) • A H Pharmaceuticals (azathioprine) • Actavis UK (azathioprine, dapsone) • Amgen (romiplostim) • Arrow Generics (azathioprine) • Baxter BioScience (intravenous anti-D immunoglobulin) • Bio Products Laboratory (intravenous normal immunoglobulin) • CSL Behring (intravenous normal immunoglobulin) • Dowelhurst (azathioprine) • Focus Pharmaceuticals (azathioprine) • Mylan UK (azathioprine, danazol) • Genus Pharmaceuticals (vinblastine) • Grifols UK (intravenous normal immunoglobulin)

Consultees	**Commentators (no right to submit or appeal)**
• United Kingdom Clinical Pharmacy Association <u>Others</u> • Department of Health • NHS South East London • North Yorkshire and York • Welsh Assembly Government	• Hospira UK (vinblastine sulphate, vincristine sulphate) • Novartis (cyclosporin) • Pfizer (cyclophosphamide) • Roche Products (mycophenolate mofetil, rituximab) • Sanofi (danazol) <u>Relevant research groups</u> • MRC Clinical Trials Unit • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <u>Evidence Review Group</u> • Aberdeen HTA Group • National Institute for Health Research Health Technology Assessment Programme <u>Associated Guideline Groups</u> • None <u>Associated Public Health Groups</u> • None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement[1], respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

[1] Non manufacturer consultees are invited to submit statements relevant to the group they are representing.